Chitosan, which is biodegradable, biocompatible, non-toxic, and mucoadhesive, is frequently employed in the creation of nasal drug delivery nanoparticles that utilize polyelectrolyte complexes. Chitosan's usage in the pharmaceutical and biomedical industries is nevertheless constrained by its reduced solubility in aqueous and alkaline conditions. This necessitates the creation of enhanced chemically modified chitosan mimics that can get beyond the solubility barrier. Using a straightforward ionic gelation process, chitosan-based polyelectrolyte complexes (PEC) were created by the interaction of positively charged chitosan with negatively charged pectin. SEM was used to study the surface morphology and revealed that smooth and rough surfaces were created by varying the counter-ions, resulting in spheres or discs. DSC and FTIR were used to validate the development of the polyelectrolyte complex. As an oral tablet, topiramate is a second-generation antiepileptic medication used to treat partial and generalized seizures. Although it is more convenient, oral administration results in delayed absorption. Additionally, because parenteral administration necessitates medical support, it is impossible in emergency situations. In order to create topiramate PEC for intranasal delivery using the ionotropic gelation process, the current study has this objective. Particle size, zeta potential, surface shape, drug content, entrapment effectiveness, in vitro drug release, and ex vivo permeation experiments in excised porcine nasal mucosa were all examined for the produced PEC. Nasal mucosa was not harmed by the optimized formulation, according to investigations on rhinocilial toxicity. Thus, a promising alternative for brain targeting and the treatment of epilepsy is the intranasal administration of topiramate utilizing chitosan